SHANG.FOS.PHARM.GR.H YC 1 (08HH) — Capital Reinvestment Ratio
Latest as of December 2025:
0.85x
SHANG.FOS.PHARM.GR.H YC 1 (08HH) has a Capital Reinvestment Ratio of 0.85x as of December 2025, meaning it reinvests 1% of its operating cash flow (€5.21 Billion) in capital expenditures (€4.45 Billion). See 08HH free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.85x
Capex / Operating Cash Flow
Operating Cash Flow
€5.21 Billion
EUR
Capital Expenditures
€4.45 Billion
EUR
Data as of
Dec 2025
Most recent filing
SHANG.FOS.PHARM.GR.H YC 1 Capital Reinvestment Ratio (2021–2025)
This chart tracks SHANG.FOS.PHARM.GR.H YC 1's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
Year-by-year Capital Reinvestment Ratio for SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025. For live market cap and broader valuation context, see how much is SHANG.FOS.PHARM.GR.H YC 1 worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.85x | €5.21 Billion | €4.45 Billion | ▼ -13.4% |
| 2024 | 0.99x | €4.48 Billion | €4.41 Billion | ▼ -37.0% |
| 2023 | 1.56x | €3.41 Billion | €5.34 Billion | ▲ +11.9% |
| 2022 | 1.40x | €4.22 Billion | €5.89 Billion | ▲ +10.6% |
| 2021 | 1.26x | €3.94 Billion | €4.97 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow